%0 Journal Article
%A Vithayathil, Mathew
%A D'Alessio, Antonio
%A Fulgenzi, Claudia Angela Maria
%A Nishida, Naoshi
%A Schönlein, Martin
%A von Felden, Johann
%A Schulze, Kornelius
%A Wege, Henning
%A Saeed, Anwaar
%A Wietharn, Brooke
%A Hildebrand, Hannah
%A Wu, Linda
%A Ang, Celina
%A Marron, Thomas U
%A Weinmann, Arndt
%A Galle, Peter R
%A Bettinger, Dominik
%A Bengsch, Bertram
%A Vogel, Arndt
%A Balcar, Lorenz
%A Scheiner, Bernhard
%A Lee, Pei-Chang
%A Huang, Yi-Hsiang
%A Amara, Suneetha
%A Muzaffar, Mahvish
%A Naqash, Abdul Rafeh
%A Cammarota, Antonella
%A Zanuso, Valentina
%A Pressiani, Tiziana
%A Pinter, Matthias
%A Cortellini, Alessio
%A Kudo, Masatoshi
%A Rimassa, Lorenza
%A Pinato, David J
%A Sharma, Rohini
%T Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
%J Hepatology international
%V 17
%N 4
%@ 1936-0533
%C Heidelberg
%I Springer
%M DKFZ-2023-00678
%P 904-914
%D 2023
%Z 2023 Aug;17(4):904-914
%X Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC.191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated.Patients in the overweight cohort (n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort (n = 97). Baseline Child-Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2
%K Anti-programmed death-ligand (Other)
%K Anti-vascular endothelial growth factor (Other)
%K Checkpoint inhibitor (Other)
%K Cirrhosis (Other)
%K Immunotherapy (Other)
%K Non-alcoholic fatty liver disease (Other)
%K Obesity (Other)
%K Overall survival (Other)
%K Overweight (Other)
%K Progression-free survival (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37005953
%R 10.1007/s12072-023-10491-3
%U https://inrepo02.dkfz.de/record/275220